ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  mercaptopurine
Find trials that include:  Any drugs shown
Results 1-25 of 26 for your search:
Start Over
Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 1 to 18
Trial IDs: TOT17, NCI-2017-00582, NCT03117751
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930
Assessing Compliance with Mercaptopurine Treatment in Younger Patients with Acute Lymphoblastic Leukemia in First Remission
Status: Active
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 12 to 20
Trial IDs: ACCL1033, NCI-2012-00105, CDR0000721559, NCT01476852, COG-ACCL1033, NCT01503632
Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 30 to 70
Trial IDs: E1910, NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01, NCT02003222
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756, NCT02883049
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 2 to 21
Trial IDs: AALL1631, NCI-2016-01588, NCT03007147
Risk Classification Schemes in Identifying Better Treatment Options for Children and Adolescents with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 21
Trial IDs: 16-001, NCI-2017-00431, NCT03020030
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 39
Trial IDs: A041501, NCI-2016-01981, NCT03150693
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2010-0991, NCI-2011-01123, NCT01371630
Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 10 and over
Trial IDs: 2014-0521, NCI-2015-00779, NCT02420717
Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and under
Trial IDs: TINI, NCI-2015-01493, NCT02553460
Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2006-0328, NCI-2012-01518, NCT00501826
Combination Chemotherapy with or without Rituximab, Imatinib Mesylate, or Dasatinib in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-0598, NCI-2011-00861, NCT01319981
Combination Chemotherapy and Ofatumumab in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2010-0708, NCI-2011-01061, NCT01363128
Risk-Directed Therapy in Treating Young Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ALLR18, NCI-2012-00587, NCT01700946
Combination Chemotherapy in Treating Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: 12-266, NCI-2013-01642, NCT01920737
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: S1318, NCI-2014-01047, SWOG-S1318, NCT02143414
Panobinostat, Bortezomib, and Vincristine Sulfate Liposome with Re-induction Therapy in Treating Younger Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: TSALV, NCI-2015-00935, NCT02518750
Azacitidine and Combination Chemotherapy in Treating Infants with Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 1
Trial IDs: AALL15P1, NCI-2016-00973, NCT02828358
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 1 to 21
Trial IDs: INCB 18424-269, NCI-2016-01687, AALL1521, NCT02723994
Blinatumomab and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 14 and over
Trial IDs: 2014-0845, NCI-2017-00596, NCT02877303
Ixazomib Citrate and Combination Chemotherapy in Treating Older Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 51 to 75
Trial IDs: 14-200, NCI-2014-02643, NCT02228772
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Phase: No phase specified
Type: Treatment
Age: 365 days and under
Trial IDs: CDR0000570260, NCI-2014-00665, EUDRACT-2005-004599-19, DCOG-INTERFANT-06, CCLG-LK-2006-10, NCT00550992
Start Over